🇺🇸 FDA
Patent

US 10093710

Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia

granted A61KA61K38/00A61K38/1793

Quick answer

US patent 10093710 (Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K38/00, A61K38/1793, A61K38/2086, A61K45/06